+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Research Report on China's Mecapegfilgrastim Market, 2021-2025

  • ID: 5504596
  • Report
  • November 2021
  • Region: China
  • 40 Pages
  • China Research & Intelligence

According to the International Agency for Research on Cancer (IARC) of the World Health Organization (WHO), China reported about 4.57 million new cancer cases in 2020, around 3 million of which were dead. Cancer treatments include surgery, radiation therapy and chemotherapy. Radiation therapy is one of the treatments that involve the use of high-energy waves (such as X-rays) to kill cancer cells. Radiotherapy can be used alone or in combination with other treatments (systemic therapy, surgery, etc.) to cure or stabilize cancer. Chemotherapy, on the other hand, uses anti-cancer drugs, and it is one of the most important methods of treating tumors at the current stage. The clinic's use of both radiotherapy and chemotherapy will cause different degrees of toxic side effects, which will also kill normal cells. In response to those side effects of chemotherapy, the dose of chemotherapy drugs is usually reduced. But as the dose is positively correlated with the efficacy, once it is reduced, the anti-tumor effect will also decrease. Then if long-acting G-CSF is used to prevent neutropenia with fever (FN) at the end of chemotherapy, the risk of FN will be reduced, greatly improving the safety of chemotherapy.






Granulocyte Colony Stimulating Factor (G-CSF) is a glycoprotein that stimulates the survival, proliferation, differentiation and activation of neutrophil progenitor cells and mature neutrophils, and plays an important role in non-specific cellular immunity against infection. G-CSF is mainly used for the prevention and treatment of leukopenia caused by radiotherapy or chemotherapy, the treatment of myelopoietic dysfunction and myelodysplastic syndrome, and the prevention of potential infectious complications of leukopenia. G-CSF currently available on the market includes filgrastim, pegfilgrastim, and mecapegfilgrastim.


According to the market research, Amgen launched Neupogen (filgrastim), the world's first recombinant human granulocyte colony-stimulating factor, on February 20, 1991, which was quickly and widely accepted clinically, and its sales value have remained stable at more than USD1 billion for the last two decades. On January 31, 2002, Amgen again, launched Neulasta (polyethylene glycol filgrastim), the world's first long-acting G-CSF drug, which has seen its market share climb all the way to a peak of USD4.72 billion in 2015 and has almost monopolized the sales of long-acting G-CSFs worldwide.


On May 18, 2018, the NMPA announced the approval of Jiangsu Hengrui Medicine's mecapegfilgrastim injection (polyethylene glycol recombinant human granulocyte-stimulating factor injection, HHPG-19K), marketed under the brand name Aido®, for the indication of adult patients with non-myeloid malignancies who are prone to febrile neutropenia because the treatment of myelosuppressive anticancer drugs, reducing the incidence of infections manifested as febrile neutropenia.


The road to market for Jiangsu Hengrui Medicine's mecapegfilgrastim in China has been very torturous. It took the company about ten years from clinical filing in 2008 to production in 2013. The company went through clinical self-examination and withdrawal, resubmission under a new generic name, public announcement of inclusion in priority review, and cancellation before its drug was finally approved for marketing.


According to the market research, the sales value of mecapegfilgrastim has grown significantly since its launch in China in 2018, reaching approximately CNY432 million (USD66.5 million) in 2020, with a CAGR of 1154% from 2018 to 2020. The analyst expects that from 2021 to 2025, with the rising number of cancer cases in China, its mecapegfilgrastim market is still able to grow significantly. Similar drugs from other Chinese pharmaceutical companies are also expected to be marketed in the coming years.


Topics Covered:

  • Impact of COVID-19 on China’s Mecapegfilgrastim Market
  • The Incidence of Cancer in China
  • Development Environment of Mecapegfilgrastim in China
  • Sales Volume of Mecapegfilgrastim in China
  • Sales Volume and Value of Mecapegfilgrastim in China by Region
  • Major Mecapegfilgrastim Manufacturers in China and Their Market Shares
  • Selling Prices of Mecapegfilgrastim in China
  • Major Mecapegfilgrastim Producers in China
  • Prospects of China’s Mecapegfilgrastim Market, 2021-2025
Frequently Asked Questions about the Chinese Mecapegfilgrastim Market

What is the estimated value of the Chinese Mecapegfilgrastim Market?

The Chinese Mecapegfilgrastim Market was estimated to be valued at ¥2.8 Million in 2018.

What is the growth rate of the Chinese Mecapegfilgrastim Market?

The growth rate of the Chinese Mecapegfilgrastim Market is 120.5%, with an estimated value of ¥695.9 Million by 2025.

What is the forecasted size of the Chinese Mecapegfilgrastim Market?

The Chinese Mecapegfilgrastim Market is estimated to be worth ¥695.9 Million by 2025.

Who are the key companies in the Chinese Mecapegfilgrastim Market?

Key companies in the Chinese Mecapegfilgrastim Market include Jiangsu Hengrui Medicine Co., Ltd..
Note: Product cover images may vary from those shown

1 Relevant Concepts of Mecapegfilgrastim
1.1 Indications of Mecapegfilgrastim
1.2 Development of China’s Mecapegfilgrastim Market
1.3 Governmental Approval of Mecapegfilgrastim in China
1.4 The Impact of COVID-19 on China’s Mecapegfilgrastim Market


2 Sales of Mecapegfilgrastim in China, 2016-2020 
2.1 Sales Value
2.1.1 Sales Value in China
2.1.2 Sales Value in China by Region
2.2 Sales Volume
2.2.1 Sales Volume in China
2.2.2 Sales Volume in China by Region
2.3 Sales of Mecapegfilgrastim in China by Dosage Form, 2016-2020
2.3.1 Injection
2.3.2 Other Dosage Forms


3 Analysis of Major Mecapegfilgrastim Manufacturers in China, 2020
3.1 Analysis of Market Share 
3.1.1 Market Share of Manufacturers by Sales Value
3.1.2 Market Share of Manufacturers by Sales Volume
3.2 Jiangsu Hengrui Medicine Co., Ltd.
3.2.1 Company Profile
3.2.2 Sales of Mecapegfilgrastim in China


4 Selling Prices of Mecapegfilgrastim of Different Companies in China, 2020-2021
4.1 Jiangsu Hengrui Medicine Co., Ltd. (Aiduo®)
4.2 Other Companies


5 Prospects of China’s Mecapegfilgrastim Market, 2021-2025
5.1 Influencing Factors for the Market Development
5.1.1 The Impact of COVID-19 on the Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend


List of Charts
Chart Patent Information of Mecapegfilgrastim in China
Chart Sales Value of Mecapegfilgrastim in China, 2016-2020
Chart Sales Volume of Mecapegfilgrastim in China, 2016-2020
Chart Sales Value of Mecapegfilgrastim Injection in China, 2016-2020
Chart Sales Value and Volume of Mecapegfilgrastim (of Jiangsu Hengrui Medicine Co., Ltd.) in China, 2016-2020
Chart Selling Price of Aiduo (Mecapegfilgrastim of Jiangsu Hengrui Medicine Co., Ltd.) in China, 2020
Chart Forecast on Sales Value of Mecapegfilgrastim in China, 2021-2025
Chart Forecast on Sales Volume of Mecapegfilgrastim in China, 2021-2025


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


Note: Product cover images may vary from those shown

Loading
LOADING...

  • Jiangsu Hengrui Medicine Co., Ltd.
Note: Product cover images may vary from those shown

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...